



## Company Overview

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has nine marketed prescription pharmaceutical products and multiple programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children's Hospital and Sentyln. For more information, visit [www.fortressbiotech.com](http://www.fortressbiotech.com).

## **UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for \$205 Million**

Feb 23 2026, 9:24 AM EST

## **Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease**

Feb 23 2026, 8:00 AM EST

## **Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States**

Jan 13 2026, 7:45 AM EST

## Management Team

### **Lindsay A. Rosenwald, M.D.**

Chairman, President and Chief Executive Officer

### **Michael S. Weiss**

Executive Vice Chairman, Strategic Development

### **David Jin**

Chief Financial Officer and Head of Corporate Development

### **Samuel Berry**

General Counsel and Corporate Secretary

---

## **Fortress Biotech, Inc.**

1111 Kane Concourse  
Suite 301  
Bay Harbor Islands, FL 33154

---

**Stock Overview**

**Symbol** FBIIO  
**Exchange** Nasdaq  
**Market Cap** 98.71m  
**Last Price** \$3.12  
**52-Week Range** \$1.32 - \$4.53

**Investor Relations**

Jaclyn Jaffe  
Nicole McCloskey  
T: 781-652-4500  
[ir@fortressbiotech.com](mailto:ir@fortressbiotech.com)

03/17/2026 08:00 PM EDT

**Disclaimer**

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.